Tantalizing results from small trials and anecdotes raised hopes that drugs like Ozempic could help. Despite setbacks, ...

A drug maker is looking for participants for a clinical trial involving an investigational Alzheimer's drug, and Baltimore is ...

Two of the most closely watched Alzheimer clinical trials of the decade have delivered a sobering verdict: GLP-1 drugs that ...

Treatment with neflamapimod slowed clinical worsening and led to reduced disease-related plasma biomarkers in individuals with dementia with Lewy bodies, according to a speaker at CTAD. “Dementia with ...

The experimental drug neflamapimod reduced a key biomarker of neurodegeneration, which correlated with a slowing of cognitive ...

Neflamapimod is an oral p38 alpha kinase inhibitor that targets dysfunction and degeneration of acetylcholine-producing ...

The Rutgers Krieger Klein Alzheimer's Research Center has received a $1.5 million philanthropic gift from the Norman and Mary ...

Microglial activity appears to determine when amyloid becomes biologically significant, reshaping how clinicians interpret ...

High-sensitivity C-reactive protein (CRP) decreased significantly in the semaglutide group, with estimated treatment ratios ...

One million people in the UK have dementia and it already kills more people than cancer or heart disease - usually from ...

When neurologist Steven Arnold is deciding whether to treat an Alzheimer's patient with a new therapy, he relies on averages.

B. Joy Snider's clinic focuses on early detection of memory issues, using biomarkers for precise Alzheimer's diagnosis and ...